Patents Examined by Mindy G Brown
  • Patent number: 9631197
    Abstract: The invention relates to a method for carrying out recombination at a target locus in a Rasamsonia cell. The invention also relates to Rasamsonia cells, for example Rasamsonia cells produced by such a process. The invention further relates to processes in which such Rasamsonia cells are used and to the resulting enzyme compositions. The invention further relates to nucleic acid and amino acid sequences.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: April 25, 2017
    Assignee: DSM IP ASSETS B.V.
    Inventors: Alrik Pieter Los, Yvonne Johannes Odilia Arendsen, Adrianus Wilhelmus Hermanus Vollebregt
  • Patent number: 9605268
    Abstract: Disclosed is a method for introducing an exogenous DNA by overcoming the restriction modification barrier of the target bacterium. The method includes the steps of 1) co-expressing all DNA-methyltransferase-encoding genes in the genome of the target bacterium in E. coli in which the restriction modification system thereof has been deleted to obtain a recombinant bacterium A, 2) introducing an exogenous DNA molecule into the recombinant bacterium A for in vivo modification so as to obtain a methylation-modified exogenous DNA molecule, and 3) introducing the methylation-modified exogenous DNA molecule into the target bacterium.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: March 28, 2017
    Assignee: Institute of Microbiology, Chinese Academy of Sciences
    Inventors: Tingyi Wen, Guoqiang Zhang, Aihua Deng
  • Patent number: 9580719
    Abstract: The present invention provides an array for rapidly identifying a host cell population capable of producing a heterologous protein with improved yield and/or quality. The array comprises one or more host cell populations that have been genetically modified to increase the expression of one or more target genes involved in protein production, decrease the expression of one or more target genes involved in protein degradation, or both. One or more of the strains in the array may express the heterologous protein of interest in a periplasm compartment or may secrete the heterologous protein extracellularly through an outer cell wall. The strain arrays are useful for screening for improved expression of any protein of interest including therapeutic proteins, hormones, growth factors, extracellular receptors or ligands, proteases, kinases, blood proteins, chemokines, cytokines, antibodies and the like.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: February 28, 2017
    Assignee: PFENEX, INC.
    Inventors: Diane M. Retallack, Charles H. Squires, Thomas M. Ramseier, Russell J. Coleman, Jane C. Schneider, Charles D. Hershberger
  • Patent number: 9580737
    Abstract: A general method and strains of bacteria are described by means where the endogeneous DNAK protein or homolog of the DNAK protein is tagged with a recognizable amino acid sequence and that through this tag, DNAK may be efficiently removed, and as such, recombinant protein purification may be greatly improved both in yield and purity with simplified purification steps that remove the DNAK and reduced cost, waste accumulation and labor, and the isolated recombinant protein will significantly benefit research and therapeutics in its application.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: February 28, 2017
    Assignee: IDEA TREE, LLC
    Inventor: Michael Longo
  • Patent number: 9580716
    Abstract: Nucleic acids encoding mutant elongation factor proteins (EF-Sep), phosphoseryl-tRNA synthetase (SepRS), and phosphoseryl-tRNA (tRNASep) and methods of use in site specific incorporation of phosphoserine into a protein or polypeptide are described. Typically, SepRS preferentially aminoacylates tRNASep with O-phosphoserine and the tRNASep recognizes at least one codon such as a stop codon. Due to the negative charge of the phosphoserine, Sept-tRNASep does not bind elongation factor Tu (EF-Tu). However, mutant EF-Sep proteins are disclosed that bind Sep-tRNASep and protect Sep-tRNASep from deacylation. In a preferred embodiment the nucleic acids are on vectors and are expressed in cells such as bacterial cells, archeaebacterial cells, and eukaryotic cells. Proteins or polypeptides containing phosphoserine produced by the methods described herein can be used for a variety of applications such as research, antibody production, protein array manufacture and development of cell-based screens for new drug discovery.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: February 28, 2017
    Assignee: Yale University
    Inventors: Hee-Sung Park, Dieter Soll
  • Patent number: 9567594
    Abstract: Nucleic acids encoding mutant elongation factor proteins (EF-Sep), phosphoseryl-tRNA synthetase (SepRS), and phosphoseryl-tRNA (tRNASep) and methods of use in site specific incorporation of phosphoserine into a protein or polypeptide are described. Typically, SepRS preferentially aminoacylates tRNASep with O-phosphoserine and the tRNASep recognizes at least one codon such as a stop codon. Due to the negative charge of the phosphoserine, Sept-tRNASep does not bind elongation factor Tu (EF-Tu). However, mutant EF-Sep proteins are disclosed that bind Sep-tRNASep and protect Sep-tRNASep from deacylation. In a preferred embodiment the nucleic acids are on vectors and are expressed in cells such as bacterial cells, archeaebacterial cells, and eukaryotic cells. Proteins or polypeptides containing phosphoserine produced by the methods described herein can be used for a variety of applications such as research, antibody production, protein array manufacture and development of cell-based screens for new drug discovery.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: February 14, 2017
    Assignee: Yale University
    Inventors: Hee-Sung Park, Dieter Soll
  • Patent number: 9567616
    Abstract: A target substance can be efficiently produced by culturing, in a medium, a coryneform bacterium in which the activity of a PTS protein relating to fructose uptake is reduced or lost as compared with a parent strain and the bacterium can produce the target substance, allowing the target substance to form and accumulate in a culture; and collecting the target substance from the culture.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: February 14, 2017
    Assignee: KYOWA HAKKO BIO CO., LTD.
    Inventors: Tetsuro Ujihara, Tetsuya Abe, Makoto Yagasaki
  • Patent number: 9567644
    Abstract: The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to RAF gene fusions as diagnostic markers and clinical targets for cancer.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: February 14, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Arul Chinnaiyan, Nallasivam Palanisamy, Shanker Kalyana-Sundaram
  • Patent number: 9566560
    Abstract: An article of manufacture having a plurality of sites in domains of regular patterns. Neighboring domains are oriented at different angles to improve the identification of the sites.
    Type: Grant
    Filed: October 6, 2011
    Date of Patent: February 14, 2017
    Assignee: Illumina, Inc.
    Inventors: Jason Harris, Stephen Tanner
  • Patent number: 9562897
    Abstract: The invention generally relates to performing sandwich assays in droplets. In certain embodiments, the invention provides methods for detecting a target analyte that involve forming a compartmentalized portion of fluid including a portion of a sample suspected of containing a target analyte and a sample identifier, a first binding agent having a target identifier, and a second binding agent specific to the target analyte under conditions that produce a complex of the first and second binding agents with the target analyte, separating the complexes, and detecting the complexes, thereby detecting the target analyte.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: February 7, 2017
    Assignee: Raindance Technologies, Inc.
    Inventors: Michael Samuels, Darren Roy Link
  • Patent number: 9561167
    Abstract: Provided are a gene involved in the regulation of the amount of melanin in keratinocytes, and the control of the color of skin or hair, the gene being selected from the group consisting of ATG7 gene, RAB11A gene, CLIP-170 gene, Rubicon gene and RAB7B gene, and a molecule encoded by the gene.
    Type: Grant
    Filed: October 31, 2011
    Date of Patent: February 7, 2017
    Assignee: Kao Corporation
    Inventors: Daiki Murase, Akira Hachiya
  • Patent number: 9562227
    Abstract: The present invention relates to a method for screening anticancer agent or SIP1/ZEB2 inhibitor using integrin alpha 5 (ITGA5), more precisely a method for measuring integrin alpha 5 expression pattern in SIP1/ZEB2 over-expressing cell line or SIP1/ZEB2 expression induced cell line, both treated with sample compounds, by comparing with that of the control. The method of the present invention facilitates screening of anticancer agent or SIP1/ZEB2 inhibitor simply by measuring integrin alpha 5 expression, so that it can be effectively applied in the field of medicine.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: February 7, 2017
    Assignee: Korea Research Institute of Bioscience & Biotechnology
    Inventors: Semi Kim, Hee Young Kang, Myoung Suk Choi, Mi-Ra Lee, Jin-San Yoo, Young Kyu Park
  • Patent number: 9562248
    Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: February 7, 2017
    Assignee: NOVOZYMES INC.
    Inventors: Ye Liu, Lan Tang, Junxin Duan
  • Patent number: 9562249
    Abstract: The present invention is directed to an innate DNA sequence within the complete genome sequence of Actinoplanes sp. SE50/110 which resembles the structure of an actinomycete integrative and conjugative element (AICE). Related AICEs were used for establishing genetic manipulation tools for other bacteria in the past. In this document, we describe the unique features of the specific AICE found in Actinoplanes sp. SE50/110 which are clearly distinct from any other known AICE as a whole, but share minor parts with varying sequence similarity with other characterized AICEs from other species.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: February 7, 2017
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Andreas Klein, Klaus Selber, Hermann Wehlmann, Winfried Rosen, Alfred Pühler, Patrick Schwientek, Jörn Kalinowski, Udo Wehmeier
  • Patent number: 9562258
    Abstract: A method for detecting the presence of a target nucleotide sequence in a sample of DNA is described herein in which a test sample comprising single stranded DNA is exposed to a DNA probe and a nicking endonuclease under conditions that would permit sequence-specific hybridization of the probe to a complementary target sequence. The probe comprises a sequence complementary to the target sequence to be detected and this sequence also includes a recognition sequence for the nicking endonuclease. If the sample contains the target sequence, the probe hybridizes to the target and is cleaved by the nicking endonuclease, which leaves the target intact. Observing the presence of probe cleaved by the nicking endonuclease indicates the presence of the target nucleotide sequence in the sample of DNA.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: February 7, 2017
    Assignee: Georgetown University
    Inventors: Mark Danielsen, Joel Credle, Eugene A. Davidson, Kenneth L. Dretchen
  • Patent number: 9562270
    Abstract: The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3q and/or 5p.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: February 7, 2017
    Assignee: NeoDiagnostix
    Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
  • Patent number: 9562912
    Abstract: Provided is a method for identifying and suppressing abnormal growth of fibroblasts at an early stage. Provided is a method for identifying the growth state of fibroblasts using as an index the level of expression of ETFB (electron transfer flavoprotein beta subunit), comprising: judging, in cases where the level of expression of ETFB is high, that there is a high probability that fibroblasts are abnormally growing; and judging, in cases where the level of expression of ETFB is low, that there is a high probability that fibroblasts are normally growing. Further, by inhibition of ETFB, abnormal growth of fibroblasts can be suppressed.
    Type: Grant
    Filed: December 27, 2011
    Date of Patent: February 7, 2017
    Assignee: POLA PHARMA INC.
    Inventors: Shigenari Hirokawa, Hiroyuki Kitajima, Tomomasa Shimanuki
  • Patent number: 9562234
    Abstract: The purpose of the present invention is to provide a technique to duplicate and translocate any large region in a chromosome of a fungus belonging to Aspergillus across a wide range, so that it will possible to stably and systematically acquire an Aspergillus strain having a novel trait, which was un-acquirable by conventional techniques. The present invention relates to a transformant of the fungus belonging to Aspergillus wherein a transformation marker gene with deficiency of a terminal part at the 5? or 3? end of its coding region is integrated into an outside of a target region in a chromosome of the fungus subject to duplicated translocation, and a transformation marker gene with deficiency of a terminal part at the 3? or 5? end of its coding region is integrated into an outside of a region in another chromosome of the fungus to be replaced with the target region.
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: February 7, 2017
    Assignee: KIKKOMAN CORPORATION
    Inventor: Tadashi Takahashi
  • Patent number: 9486486
    Abstract: The present invention relates to a novel bacterial strain isolated and characterized from groundwater. The invention also relates to bacterial extracts and to the therapeutic use of same, notably in the context of the treatment of inflammations.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: November 8, 2016
    Assignees: PIERRE FABRE DERMO-COSMETIQUE, PIERRE FABRE MEDICAMENT
    Inventors: Nathalie Castex-Rizzi, Thien Nguyen, Christine Libon, Bertrand Chol
  • Patent number: 9481914
    Abstract: The present invention relates to methods for the diagnosis of bacterial vaginosis based on an analysis of a patient sample. For example, patient test samples are analyzed for the presence or absence of one or more lactobacilli and two or more pathogenic organisms. The presence or absence of one or more lactobacilli and two or more pathogenic organisms may be detected using PCR analysis of nucleic acid segments corresponding to each target organism. The quantity of the target organisms can then be used to determine a score which is indicative of a diagnosis of bacterial vaginosis.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: November 1, 2016
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Erik P. Johnson, Dale A. Schwab